ArticleTranslational cancer research2026
Low-dose radiotherapy combined with immune checkpoint inhibitors in advanced malignancies: a real-world exploratory study.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with advanced malignancies often have limited treatment options after failure of systemic therapy, and the prognosis remains poor. Low-dose radiotherapy (LDRT) has been proposed to enhance antitumor immunity and may improve the efficacy of immune checkpoint inhibitors (ICIs). We aimed to evaluate the clinical activity and safety of LDRT combined with ICIs in patients with advanced malignancies in a real-world clinical setting. Methods: This single-center retrospective real-world study included patients with advanced malignancies treated at Taikang Xianlin Drum Tower Hospital who received LDRT (2 Gy × 3 fractions, total dose 6 Gy) directed to progressive lesions in combination with programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors. Clinical characteristics, treatment details, tumor response, follow-up data, and treatment-related adverse events were retrospectively collected and analyzed. The primary endpoints were objective response rate (ORR) and progression-free survival (PFS), while the secondary endpoint was disease control rate (DCR). Safety was assessed according to the incidence of treatment-related adverse events. Results: Thirteen patients with various advanced malignancies were included in the analysis. The ORR was 38.5% and the DCR was 76.9%. The median PFS was 6.7 months. Notably, all documented disease progression occurred outside the irradiated fields, whereas the irradiated lesions remained locally controlled during follow-up. Treatment-related adverse events were mainly chemotherapy-related hematologic toxicities. No clinically significant immune-related adverse events, radiotherapy-related toxicities, or treatment-related deaths were observed. Conclusions: LDRT combined with ICIs showed preliminary clinical activity with acceptable tolerability in this small real-world cohort of patients with advanced malignancies. Although limited by the small sample size, this approach may represent a feasible treatment option for selected patients and should be further evaluated in prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.